US 12,102,710 B2
Probiotic skin formulations
Thomas M. Hitchcock, Dallas, TX (US); Sasima Phadungpojna, Bristol, TN (US); Matthew D. Stephens, Kingsport, TN (US); and Mun Su Rhee, Johnson City, TN (US)
Assigned to CROWN LABORATORIES, INC., Johnson City, TN (US)
Filed by CROWN LABORATORIES, INC., Johnston City, TN (US)
Filed on Jun. 22, 2021, as Appl. No. 17/353,956.
Claims priority of provisional application 63/042,684, filed on Jun. 23, 2020.
Prior Publication US 2021/0393510 A1, Dec. 23, 2021
Int. Cl. A61K 8/99 (2017.01); A61K 8/02 (2006.01); A61K 8/04 (2006.01); A61K 8/19 (2006.01); A61K 8/34 (2006.01); A61K 8/37 (2006.01); A61K 8/67 (2006.01); A61K 8/73 (2006.01); A61K 8/88 (2006.01); A61K 8/92 (2006.01); A61K 8/9789 (2017.01); A61K 9/06 (2006.01); A61K 9/19 (2006.01); A61K 31/07 (2006.01); A61K 35/741 (2015.01); A61K 47/14 (2017.01); A61K 47/34 (2017.01); A61K 47/44 (2017.01); A61K 47/46 (2006.01); A61Q 19/00 (2006.01)
CPC A61K 8/99 (2013.01) [A61K 8/022 (2013.01); A61K 8/042 (2013.01); A61K 8/19 (2013.01); A61K 8/34 (2013.01); A61K 8/37 (2013.01); A61K 8/671 (2013.01); A61K 8/735 (2013.01); A61K 8/88 (2013.01); A61K 8/922 (2013.01); A61K 8/9789 (2017.08); A61K 9/06 (2013.01); A61K 9/19 (2013.01); A61K 31/07 (2013.01); A61K 35/741 (2013.01); A61K 47/14 (2013.01); A61K 47/34 (2013.01); A61K 47/44 (2013.01); A61K 47/46 (2013.01); A61Q 19/00 (2013.01); A61K 2800/524 (2013.01); A61K 2800/594 (2013.01)] 2 Claims
 
1. A dermatological composition consisting of:
an anhydrous formulation of:
about 0.1% to about 5% by mass of a dry growth-arrested genetically modified strain of Cutibacterium acnes (C. acnes) that remains in a dormant state for at least six months and up to about 2 years;
about 55% to about 95% by mass of one or more anhydrous emollients comprising ethyl olivate or Olea europaea leaf extract; and
about 1% to about 15% by mass of one or more anhydrous gelling agents comprising Polyamide-3.